Regenicin's PermaDermâ?¢ to be highlighted at Armed Forces media event
A regenerative medicine product called PermaDerm™ which promises to grow as much skin as needed to treat burn victims, those with chronic wounds and others may be poised to move the stock of an otherwise unknown, regenerative cell therapy company which only recently began trading on Wall Street's often wild, over the counter bulletin board exchange .
According to many of those familiar with the technology developed by the Switzerland-based Lonza Group, the science is quite real and has already been quietly deployed to help over 100 children who suffered severe burns over a large area of their bodies. The tissue-engineered skin is prepared in Lonza's labs from a postage stamp sized sample of the patient's own skin. Cells develop in special dishes and form both the epidermal and dermal skin layers which can then be transferred to the patients without fear of rejection.
In late August, Regenicin, Inc. (OTCBB:WDST) licensed the technology from Lonza after setting their sights on commercializing the product in the United States. "There is a $3 billion market just for chronic burns in the U.S. alone," explains Regenicin's Chief Executive Officer, Randall McCoy- himself a burn victim. "We want to provide additional indications beyond burns. We want to go after chronic wounds." In the U.S. the market to treat diabetic ulcers and foot ulcers I said to be in excess of $8 billion.
On Tuesday morning, the micro-cap company announced that it will be presenting and participate in an event to celebrate the newest advancements in regenerative medicine on November 9th, 2010 in Walkersville, MD.
Speaking alongside representatives from the Armed Forces Institute of Regenerative Medicine, the U.S. Department of Defense Office of Technology Transition; members of Congress, U.S. Armed Forces personnel, scientists, firefighters, and surgeons and others on the frontlines of treating burns and wounds in the U.S. military, the company will speak in more detail about their role in commercializing the ground-breaking therapeutic candidate.
Published reports have speculated about an announcement that may be made at the event, including talk of pending government grants totaling in the tens of millions of dollars to help support PermaDerm's™ development and push through the regulatory process at the FDA. Whether or not those reports are accurate, the company has clearly already distinguished itself from hundreds of other regenerative medicine companies by being asked to participate in the forum.
Speaking on behalf of Regenicin will be Dr. Craig Eagle, a member of Regenicin's Board of Directors, and head of Oncology for Pfizer Worldwide. Eagle is but one of a number of scientist who have recently joined the company's board on their own accord.
Look for the penny stock priced shares of Regenicin to climb in anticipation of the event and beyond.
